InnoCare Pharma Limited provided earnings guidance for the year ended 31 December 2023. Based on a preliminary estimate by the finance department, the net loss attributable to owners of the parent company in 2023 is expected to be approximately RMB 656 million, representing a decrease in loss of approximately 26% as compared with the corresponding period of the previous year. The net loss after excluding non-recurring gains or losses attributable to owners of the parent company was approximately RMB 654 million, representing a decrease of approximately 32% as compared with the corresponding period of the previous year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.1 HKD | -1.35% | -2.67% | -25.98% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.98% | 1.32B | |
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- 9969 Stock
- News InnoCare Pharma Limited
- InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023